|
|
|
|
|
|
| Advertisement |
 |
|
|
| 2019 Pipeline |
|
|
Pharm Exec's 2019 Pipeline Report |
This year's Pipeline Report sees CAR-T therapy eyeing new territory, cannabis-based agents targeting CNS and rare genetic disorders, the advancement of non-opioid alternatives, and the untangling of the path to market for biosimilars.
... /Read more/ |
|
|
| Advertisement |
Patient Assistance Centers of Excellence: The Next Generation of Brand Support
On Demand
 Learn More
|
|
| Trends |
 |
|
Steadying the Path of Good Science
|
As this year's Pipeline Report illustrates, there remains an imbalance between funding and incentivizing new drug discovery in some therapeutic areas and rewarding the risk-based nature of these innovations. Imagine if we could solve this conundrum in science?
... /Read more/ |
|
|
| Advertisement |
Bringing Intelligence to Drug Discovery The Importance of Contextual Information at All Levels
On Demand
 Learn More
|
|
| Analyzing the Pharma Pipeline |
 |
|
The Pharm Exec Podcast: Episode 20
|
Pharm Exec Editorial Director Lisa Henderson and European Editor Julian Upton talk with Michelle Maskaly and Christen Harm about the magazine's recent pharmaceutical pipeline report which was published in the November 2018 issue. Topics include cannabis, CAR-T therapy, opioids, biosimilars, and Alzheimer's.
... /Read more/ |
|
|
|
ADVERTISEMENT
 
|
|
|
| Advertisement |
 |
|
|
| Biopharma |
|
|
Biopharma Business Check
|
The increase in new drug approvals and candidates in development are good signs for pharma & biotech, but both sectors face continued pricing, cost, and policy-related challenges, writes Peter Young.
... /Read more/ |
|
|
|
|
|
|
|
|
